K. Stevinson

Real‐world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

P. Ascierto, A. Arance, P. Mohr, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

J. Malvehy, V. Guillem, E. Espinosa, 2016, Melanoma research.

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)

M. Weichenthal, P. Ascierto, A. Arance, 2017, The oncologist.

Patient-Reported Utility on Pembrolizumab (Pembro) and Ipilimumab (Ipi) among Ipi Naïve Patients with Advanced Melanoma

D. Hille, W. Zhou, K. Stevinson, 2016 .

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices

J. Black-Shinn, J. Frytak, Frank X Liu, 2017, Journal of immunotherapy.

Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.

Frank X Liu, B. Chmielowski, J. Pellissier, 2017, Journal of managed care & specialty pharmacy.

Direct costs associated with adverse events of systemic therapies for advanced melanoma

J. Mauskopf, Frank X Liu, C. Copley-Merriman, 2018, Medicine.

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).

C. Dooms, G. Shapiro, F. Barlesi, 2021 .

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review

T. Yoshino, J. Strickler, D. Modest, 2023, The oncologist.

Cost effectiveness analysis of the New Jersey rapid testing algorithm for HIV testing in publicly funded testing sites.

S. Marcella, S. Paul, Eugene G. Martin, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.